Remission of diabetes (no longer having diabetes, at least for a period) is clearly attainable for some, possibly many, patients but is currently very rarely achieved or recorded. Greater awareness, documentation, and surveillance of remissions should improve health outcomes and reduce healthcare costs.
Changing management
In keeping with trends in most medical specialties, diabetes management is beginning to focus on reversible underlying disease mechanisms rather than treating symptoms and subsequent multisystem pathological consequences. 3 4 Both (epi)genetic predisposition and ageing have a role in type 2 diabetes, but it is rare without weight gain. In contrast, consistent evidence shows that weight loss is associated with extended life expectancy for people with diabetes, and that weight loss of around 15kg often produces total biochemical remission of type 2 diabetes, restoring beta cell function and. 6 7 Recognition that accumulation of ectopic fat in the liver and pancreas impairs organ function o cause type 2 diabetes, but is reversible, has raised awareness that remission is possible. 7 Media attention has encouraged increasing numbers of people with type 2 diabetes to lose weight and shed the diagnosis. Remission produces a strong sense of personal achievement and empowerment, and also benefits medical systems because patients no longer require antidiabetes drugs. The UK NHS currently spends almost £1bn (€1bn; $1.3bn) a year (£22m a day) on antidiabetes drugs, and costs are rising worldwide as diabetes rates and drug prices escalate.
Criteria for remission of diabetes
There is no final consensus on the criteria for declaring a remission of diabetes. The published criteria, and thus reported remission rates, vary, but all require being below the World Health Organization/American Diabetes Association (ADA) diagnostic thresholds for diabetes ( 
Potential metabolic value of remission
Clinical outcomes for people with type 2 diabetes are all worse at higher glucose or HbA1c concentrations. 10 No study has yet reported outcomes for people who achieve remission, but good glycaemic control through drug treatment improves microvascular outcomes (retinopathy, neuropathy, nephropathy) in both type 1 and type 2 diabetes. 11 Reduced cardiac events have also been observed in patients with type 2 diabetes after bariatric surgery. 12 In contrast, some drug trials have indicated increased mortality when HbA1c approaches normal levels, probably through hypoglycaemia provoking arrhythmias. 13 Look AHEAD, a trial of lifestyle intervention in patients with mean diabetes duration of five years, reported 11.5% remission at 12 months with 8.6% weight loss, but that proportion fell by about 30% annually. 10 Health outcomes of participants have not yet been reported, but the limited evidence and first principles suggest that remission of diabetes (without antidiabetes drugs) should enhance overall prognosis, becoming a primary management target as early as possible after diagnosis.
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Coding for health records
Remission of type 2 diabetes can be inferred from routine records of patients labelled diabetic who have non-diabetic biochemical test results (usually HbA1c<48 mmol/mol), when there is no record that antidiabetes drugs are prescribed. 14 In the UK, clinicians have used Read codes to record patients' findings and procedures since 1985 15 but are now converting to the international SNOMED system. The basic coding framework will remain, however.
The Read code [Q to A OK? yes] dictionary includes codes 21263 or 212H for "diabetes resolved" and C10P for "diabetes in remission." Diabetes resolved is used for patients misdiagnosed with diabetes or in whom diabetes was secondary to a factor that has since been removed, such as withdrawal of steroid treatment. Such patients do not require annual reviews or surveillance. Code C10P should be used for patients who have achieved remission of type 2 diabetes, usually by substantial weight loss. These patients may be considered non-diabetic for matters such as insurance, driving, or employment but as the code is diagnostic they will remain scheduled for annual reviews and retinal screening programmes.
Achieving remission
In the few countries with data, patients are seldom recorded as having diabetes in remission.
Karter and colleagues found remissions in only 0.14% of 120 000 US patients followed for seven The drivers and barriers to successful remission are not fully evaluated but are likely to include age, body mass index, duration of diabetes, HbA1c concentrations, and drug treatment.
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Physical and social environments, emotional states, and self regulatory skills are important factors affecting adherence to a weight management intervention. 19 It is unknown whether the degree of weight loss needed to achieve remission will be the same for Asian people, who commonly develop type 2 diabetes at a lower body mass index than people of European origin, but probably with similar body fat content.
Doctors may be understandably reluctant to redefine a patient as "in remission" if they are concerned that the remission, dependent on maintaining weight loss, may not persist, and that routine recall for annual checks might cease. However, under the remission coding annual reviews and screening recalls will continue. Another UK specific factor may have been fear of losing the incentive payments for managing diabetes under the Quality and Outcomes
Framework (QOF). Again, coding "diabetes in remission" retains the diagnostic status so the practice payment would continue.
Diabetes in remission has not been specifically rewarded as a management target in QOF. 
Benefits of remission
Achieving remission has health benefits for patients and removes the burden of daily monitoring and treatment, but correct coding of remission has multiple further benefits. It removes the stigma of having diabetes and provides a sense of personal achievement and social status (box 1).
Box 1: Benefits of coding remission of diabetes For patients
• Removes personal and social stigmatisation as diseased or "diabetic"
• Provides a target and a reward for the sustained hard work usually necessary to achieve and maintain substantial weight loss • May permit life insurance, mortgages, travel insurance, etc without the higher premiums added for people with a diagnosis of type 2 diabetes • Removes some occupational restrictions 
Moving forward
It is in everybody's interest to reclassify people with type 2 diabetes when they become nondiabetic. Official guidelines and international consensus for recording diabetes in remission are needed. We have proposed that two non-diabetic test results, at least two months apart, should be required, with annual reviews of HbA1c to confirm continuation ( 
